STOCK TITAN

Novavax (NVAX) director Rachel King exercises RSUs, granted new options and RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Novavax director Rachel K. King reported equity compensation activity and no share sales. On June 20, 2026 she exercised 18,880 restricted stock units (RSUs), receiving 18,880 shares of common stock, bringing her direct common stock holdings to 44,070 shares.

On June 18, 2026 she received two new awards under Novavax’s Amended and Restated 2015 Stock Incentive Plan: 14,180 RSUs and a stock option for 21,270 shares of common stock at an exercise price of $9.13 per share. The footnotes state that 100% of the new RSUs and option shares will vest on the first anniversary of the June 18, 2026 grant date, subject to her continued service on the board.

Positive

  • None.

Negative

  • None.
Insider King Rachel K.
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 18,880 $0.00 --
Exercise Common Stock 18,880 $0.00 --
Grant/Award Stock Option (Right to Buy) 21,270 $0.00 --
Grant/Award Restricted Stock Units 14,180 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 44,070 shares (Direct, null); Stock Option (Right to Buy) — 21,270 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
RSUs exercised 18,880 shares RSUs converted into common stock on June 20, 2026
Common shares held 44,070 shares Direct common stock holdings after June 20, 2026
New RSU grant 14,180 units RSUs granted on June 18, 2026
New option grant 21,270 shares Stock option covering common stock granted June 18, 2026
Option exercise price $9.13 per share Conversion or exercise price for new stock option
Derivative exercises 18,880 shares Exercise or conversion of derivative securities per transaction summary
Restricted Stock Units financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Amended and Restated 2015 Stock Incentive Plan financial
"shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest"
stock option financial
"shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest financial
"One hundred percent (100%) of the RSUs subject to this grant ... will vest on the first anniversary"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
contingent right financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
King Rachel K.

(Last)(First)(Middle)
21 FIRSTFIELD ROAD

(Street)
GAITHERSBURG MARYLAND 20878

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
NOVAVAX INC [ NVAX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/20/2026M18,880A(1)44,070D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$9.1306/18/2026A21,270 (2)06/18/2036Common Stock21,270$021,270D
Restricted Stock Units(1)06/18/2026A14,180 (3) (3)Common Stock14,180$014,180D
Restricted Stock Units(1)06/20/2026M18,880 (4) (4)Common Stock18,880$00D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
2. One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
3. One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
4. One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
/s/ Mark J. Casey, Attorney-in-Fact06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Novavax (NVAX) director Rachel K. King report?

Rachel K. King reported only equity acquisitions. She exercised 18,880 RSUs into common shares and received new grants of 14,180 RSUs and a stock option for 21,270 shares as board compensation, with no reported share sales.

How many Novavax (NVAX) common shares does Rachel K. King hold after these transactions?

After exercising 18,880 RSUs, Rachel K. King directly holds 44,070 shares of Novavax common stock. This figure reflects her position following the reported June 20, 2026 transaction and does not include unvested RSUs or unexercised options.

What new equity awards did Novavax (NVAX) grant to Rachel K. King?

Novavax granted Rachel K. King 14,180 restricted stock units and a stock option covering 21,270 shares of common stock at a $9.13 exercise price. Both awards were made under the Amended and Restated 2015 Stock Incentive Plan as amended.

When do Rachel K. King’s new Novavax (NVAX) RSUs and options vest?

The filing states that 100% of the RSUs and 100% of the stock option shares granted on June 18, 2026 will vest on the first anniversary of that grant date, provided she continues serving on Novavax’s board of directors through the vesting date.

Did Rachel K. King sell any Novavax (NVAX) shares in this Form 4 filing?

No sales are reported. The Form 4 shows only acquisitions: an exercise of 18,880 RSUs into common stock and new grants of 14,180 RSUs and a stock option for 21,270 shares, all categorized as acquisition transactions.